glp 1 drugs and gallbladder GLP-1 Risk: What Clinicians Should Watch GLP-1 receptor agonists and gallbladder

In summary, tirzepatide achieved more pronounced HbA1c reductions with a lower incidence of hypoglycemia at week 52 compared to insulin glargine

Some users do lose weight, but that usually reflects diet, activity, and motivation changes happening at the same time, not the patch itself crossing the skin barrier and acting like a drug

10.1056/NEJMoa1901118 [DOI] [PubMed] [Google Scholar] 63

Greater doses provided greater weight loss and caused more side effects such as upset stomach and, in rare instances, dysesthesia (2.3%4.5% of those enrolled)

Clinical Guidelines and Research Evidence Leading medical organizations, such as KDIGO (Kidney Disease: Improving Global Outcomes) and the American Diabetes Association, endorse GLP-1 receptor agonists for individuals with type 2 diabetes and CKD

Lowering inflammatory cytokines Studies in Nature and Diabetes show that GLP-1 reduces cytokines such as TNF-alpha, IL-6, and IL-1, which are major players in autoimmune diseases and arthritis